Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex reported that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary and key secondary endpoints, and the company is discontinuing development in that indication. The drug showed a favorable safety profile in the study.
From the press release
HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met. While some benefit from barzolvolimab treatment was observed, these improvements did not meet the Company’s internal hurdle rate for continued development. Data suggest that while mast cells contribute to AD, they are not a primary driver of the disease. Based on these results, Celldex is discontinuing development in AD. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile.
As published for republication. The full text is at GlobeNewswire.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 4:01 PM ESTRead at GlobeNewswire (opens in a new tab)
- Investing.comfirst at Nov 19, 2026, 4:04 PM ESTRead at Investing.com (opens in a new tab)
Story so far
Reported by 2 sources
Celldex reported that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary and key secondary endpoints, and it is discontinuing development in that indication.
- Nov 19, 2026, 4:01 PM EST · GlobeNewswire · this storyConfirmedCelldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis
- Nov 19, 2026, 4:04 PM EST · Investing.comConfirmedCelldex discontinues atopic dermatitis program after trial miss
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.